- Previous Rank-
- Revenue 3 Yr Annual Growth Rate55%
- Revenue 3 Yr Growth Rank10
- EPS 3 Yr Annual Growth Rate97%
- EPS 3 Yr Growth Rank8
- Total Return 3 Yr Annual Rate-
- Total Return 3 Yr Rank95
Specialty drugmaker Akorn produces generic and branded prescription drugs in hard-to-make dosages like oral liquids and injectables.
Company Information
Revenue and net income for the four quarters ended on or before April 30, 2017. Total return for the period ended June 30, 2017.
| Location | Lake Forest, Ill. |
| Industry | Pharmaceuticals |
| Sector | Health Care |
| Current Streak | - |
| Years on List | 1 |
| CEO | Rajat Rai |
| Website | http://www.akorn.com |
Looking for leads, investment insights, or competitive intelligence?Purchase Now
Revenue, Net Income
| Revenue past four quarters ($M) | $1,102 |
| Net Income past four quarters ($M) | $183 |
Growth Rates and Ranks
| Revenue 3 Yr Growth Rank | 10 |
| Revenue 3 Yr Annual Growth Rate | 55% |
| EPS 3 Yr Growth Rank | 8 |
| EPS 3 Yr Annual Growth Rate | 97% |
| Total Return 3 Yr Rank | 95 |
| Total Return 3 Yr Annual Rate | - |
| Beat S&P 500 (9.6%) | no |
| P/E Ratio | 22 |